Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation.
about
Mesothelin-Targeted CARs: Driving T Cells to Solid TumorsPhysical biology in cancer. 4. Physical cues guide tumor cell adhesion and migrationGiant obscurins regulate the PI3K cascade in breast epithelial cells via direct binding to the PI3K/p85 regulatory subunitDistinct signaling mechanisms regulate migration in unconfined versus confined spacesProbing cell traction forces in confined microenvironments.MUC16 (CA125): tumor biomarker to cancer therapy, a work in progressMesothelin Immunotherapy for Cancer: Ready for Prime Time?Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG.Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.Loss of giant obscurins from breast epithelium promotes epithelial-to-mesenchymal transition, tumorigenicity and metastasis.Fluid shear promotes chondrosarcoma cell invasion by activating matrix metalloproteinase 12 via IGF-2 and VEGF signaling pathways.By activating matrix metalloproteinase-7, shear stress promotes chondrosarcoma cell motility, invasion and lung colonization.Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor ProgressionMUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism.Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets.Unique cellular interactions between pancreatic cancer cells and the omentumT Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.Interplay of the physical microenvironment, contact guidance, and intracellular signaling in cell decision making.MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism.Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.Engineered Models of Confined Cell Migration.The need for effective pancreatic cancer detection and management: a biomarker-based strategy.DUSP28 links regulation of Mucin 5B and Mucin 16 to migration and survival of AsPC-1 human pancreatic cancer cells.In vitro and in vivo targeting imaging of pancreatic cancer using a Fe3O4@SiO2 nanoprobe modified with anti-mesothelin antibody.Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.A Panel of CA19-9, Ca125, and Ca15-3 as the Enhanced Test for the Differential Diagnosis of the Pancreatic Lesion.Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells.Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium.Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy.Transmembrane Mucins: Signaling Receptors at the Intersection of Inflammation and Cancer.CAR T-cell therapy for pancreatic cancer.Mesothelin-specific Immune Responses Predict Survival of Patients With Brain Metastasis.Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1.Amatuximab and novel agents targeting mesothelin for solid tumors.Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.E-selectin-mediated rolling facilitates pancreatic cancer cell adhesion to hyaluronic acid.Advances in systemic therapy for malignant mesothelioma: future perspectives.The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.
P2860
Q26778759-560BA480-F70D-4CF8-90A1-284FDF745322Q26863598-2023CF78-0D2F-4584-9CFB-022DCE78E13AQ30008900-176F7BEB-C87D-474A-99D6-5875720F0D81Q30414448-031D1AC9-206B-429E-8308-86FF8F420B0EQ33615751-00AFC54E-18FF-445D-BB71-B5D2C815EB15Q33713506-9716DB0D-9FD5-413F-BFDA-C93346DC5E3BQ33816551-DB7333F6-731D-45DE-9E05-219B5CCEB180Q33929696-F9C37ED6-4475-4107-B0C9-6FB553DA8A19Q35119802-7649219A-E242-4829-A55E-3A40E514B2FBQ35552059-A7CFC9DC-19E4-4E93-9360-218FA7797CEBQ35589559-C7BF3569-D3FB-4DD6-963D-EE5F16B02D6FQ35672174-B2A01E69-C7BA-4804-8134-98C3FF4EE5E6Q35832318-6FD5A679-274B-4D34-86DE-FC23482CAD14Q35837444-A43B9960-FC05-4721-8635-42EA24066D39Q36326344-9110B008-99CE-4024-ACC8-A18301BF76E5Q36328299-CF07FC32-D630-4139-AE04-B218653BD6DDQ36410426-C2F0171F-6918-4C89-B66A-9AC80262415CQ36494634-EBC34E02-06C2-4957-9B57-019969949660Q36913797-069FC9D9-5710-439F-A42B-4D4CC304B543Q37033307-51B2DB7E-F49F-4A30-8D57-DCA23346D750Q37367593-6BDBC320-77E0-40CD-8134-7E7947F48271Q37499806-A526D80A-46DF-4793-931E-8AE9F6780539Q37724995-E48F6252-F4C4-4CA6-96E0-3FDBB097EEE9Q38591066-981E298C-411A-4D6F-9AF2-DD75E3F72DFAQ38737073-8643B767-A152-418C-89D8-EE53284B2FB3Q38765928-5C0598B2-F5EB-4FF0-AE01-CDE655D437F5Q38773361-13CDF046-0A37-411F-B377-14D2B7D60344Q38868263-D749B3AB-4A95-494D-B77F-82DBF10EB679Q38908575-352E1EC3-835D-4E5E-8CA5-C48B95FC872FQ38957886-A237639A-56F4-4F1C-9A8B-A6668EA32E06Q39028976-8385834B-2605-4E12-8365-5444A10458ECQ39067183-EA0E85C6-6B71-44C8-B648-03D6359CF848Q39202440-4A2DFFD2-BF33-4B21-86BD-906558507CC9Q40049272-55770DDC-ECE7-4CDC-8181-D2E299DC86AAQ47096729-6ECFF308-5441-480E-8812-164A019838D6Q47126660-56D23833-933E-4449-9D0B-A4DD224620BEQ47309343-63D128A4-F756-4BC9-957C-DE750CC90A6EQ47855498-BEF5628C-16B9-46F1-A172-B4C3747A80F1Q47912434-B773637E-DB77-4313-B6AF-F6A0B6485215Q48098689-E136DC8A-E9F5-4D2B-B91F-374E70CD64CB
P2860
Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Mesothelin binding to CA125/MU ...... invasion via MMP-7 activation.
@en
type
label
Mesothelin binding to CA125/MU ...... invasion via MMP-7 activation.
@en
prefLabel
Mesothelin binding to CA125/MU ...... invasion via MMP-7 activation.
@en
P2093
P2860
P356
P1433
P1476
Mesothelin binding to CA125/MU ...... invasion via MMP-7 activation.
@en
P2093
Colin Paul
Konstantinos Konstantopoulos
Shih-Hsun Chen
Wei-Chien Hung
P2860
P2888
P356
10.1038/SREP01870
P407
P577
2013-01-01T00:00:00Z
P5875
P6179
1034394966